Evidence map›Paper›PMID 38548966›Full record

ArticleOncogene2024

Targeting STING elicits GSDMD-dependent pyroptosis and boosts anti-tumor immunity in renal cell carcinoma.

Shengpan Wu, Baojun Wang, Hongzhao Li, Hanfeng Wang, Songliang Du, Xing Huang, Yang Fan, Yu Gao, Liangyou Gu, Qingbo Huang and 4 more

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Mechanistic insights into gasdermin-mediated pyroptosis.Nature reviews. Molecular cell biology · 2025
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Shengpan Wu *Department of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Baojun Wang *Department of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Hongzhao Li *Department of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Hanfeng WangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Songliang DuDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.ORCID 0000-0002-8156-0792
Xing HuangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Yang FanDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Yu GaoDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Liangyou GuDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Qingbo HuangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.ORCID 0000-0003-2894-0187
Jianjun ChenSchool of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, 510515, China.
Xu ZhangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China. xzhang301@163.com.ORCID 0000-0002-6908-6768
Yan HuangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China. dr.huangyan301@foxmail.com.
Xin MaDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China. mxin301@126.com.ORCID 0000-0001-8257-4670
Chinese PLA General Hospital · CNSouthern Medical University · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81970665National Natural Science Foundation of China (National Science Foundation of China) 82103594
6 · The paper itself

Abstract

While Stimulator-of-interferon genes (STING) is an innate immune adapter cruicial for sensing cytosolic DNA and modulating immune microenvironment, its tumor-promoting role in tumor survival and immune evasion remains largely unknown. Here we reported that renal cancer cells are exceptionally dependent on STING for survival and evading immunosurveillance via suppressing ER stress-mediated pyroptosis. We found that STING is significantly amplified and upregulated in clear cell renal cell carcinoma (ccRCC), and its elevated expression is associated with worse clinical outcomes. Mechanically, STING depletion in RCC cells specifically triggers activation of the PERK/eIF2α/ATF4/CHOP pathway and activates cleavage of Caspase-8, thereby inducing GSDMD-mediated pyroptosis, which is independent of the innate immune pathway of STING. Moreover, animal study revealed that STING depletion promoted infiltration of CD4

Indexed as

Carcinoma, Renal CellIntracellular Signaling Peptides and ProteinsKidney NeoplasmsMembrane ProteinsPhosphate-Binding ProteinsPyroptosisActivating Transcription Factor 4AnimalsCell Line, TumorGasderminsHumansMiceProteolysis Targeting ChimeraSignal TransductionSTING ProteinTranscription Factor CHOPActivating Transcription Factor 4ATF4 protein, humanGasderminsGSDMD protein, humanIntracellular Signaling Peptides and ProteinsMembrane ProteinsPhosphate-Binding ProteinsProteolysis Targeting ChimeraSTING1 protein, humanSTING ProteinTranscription Factor CHOP

Identifiers

PMID38548966
OpenAlexW4393253761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.